Leadership

P. Gabriel Steg, MD

p-gabriel-steg

Professor of Cardiology at the Université Paris – Diderot, Sorbonne-Paris Cité

Professor at the National Heart and Lung Institute, Imperial College, London, UK

Dr. Steg has been a Professor of Cardiology at the Université Paris – Diderot, Sorbonne-Paris Cité, since 1994. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK since 2013. He works as an interventional cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, a large academic institution affiliated with Assistance Publique-Hôpitaux de Paris, in Paris, France. He is also Director of the “Clinical Research in Atherothrombosis” Research Team, created in 2008 at INSERM U-698, Hôpital Bichat, Paris and a co-coordinator of the Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling) affiliated with INSERM, Université Paris Diderot and Assistance Publique – Hôpitaux de Paris. He is chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research organization, which is a member of the VIGOUR collaboration.

Dr. Steg’s research interests are in the field of coronary artery disease. He is involved in studies of intervention in acute coronary syndromes, but has also turned his attention to the epidemiology of atherothrombosis and atrial fibrillation. He is a former member of the Board of the French Society of Cardiology. He is an honorary member of the Institut Universitaire de France, a fellow of the European Society of Cardiology, and American College of Cardiology. He received the silver medal of the European Society of Cardiology in 2011.

Dr Steg is currently chairing or participating in the leadership of large clinical trials or registries, he was DSMB or CEC member or chair for several large trials. He has authored more than 600 articles in peer-reviewed international journals, and is a member of the editorial board for Circulation, Circulation: Cardiovascular Interventions, and the European Heart Journal, He is the Editor-in-Chief of the french edition of Theheart.org and Editor-in-Chief for Medscape France. Dr. Steg was also co-chair of the ESC task force in charge of the 2012 Guidelines for management of ST-segment elevation myocardial infarction.

Contact:
Université Paris Diderot
INSERM U-698
Département de Cardiologie, Hôpital Bichat
Assistance Publique – Hôpitaux de Paris
46, rue Henri Huchard75877
Paris cedex 18, France
Phone: +33 1 40 25 86 68
Fax : +33 1 40 25 88 65

Publications

Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.


Leonardi S, Lopes RD, Steg PG, Abnousi F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, Stone GW, Gibson CM, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, Mahaffey KW.

Consistent Reduction in Peri-Procedural Myocardial Infarction with Cangrelor as Assessed by Multiple Definitions: Findings from CHAMPION PHOENIX.


Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA; CHAMPION PHOENIX Investigators.

On the use of propensity scores in case of rare exposure.


Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA; CHAMPION PHOENIX Investigators.

Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention.


Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Weisz G, Colombo A, Pocock S, Mehran R.

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.


Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.


Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG.

For additional research publications please visit: https://www.researchgate.net/profile/Philippe_Steg